trial

Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia

NCTId NCT03818516
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 12 (actual)
Sponsored by Emory University
Primary completion 2022-03-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2020-08-31
Primary completion
2022-03-01
Eligibility
ALL · 18 Years · 59 Years

Interventions & indications

Drugs
Oral Glucose Tolerance Test (OGTT)

Sponsors

Emory UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
David R Goldsmith, MDPrincipal Investigator

Sites

6 total
Atlanta, United StatesAtlanta, United StatesAtlanta, United StatesAtlanta, United StatesAtlanta, United StatesAtlanta, United States

Facts & assertions

4 sourced
Enrollment
12
Phase
NA
Primary Completion Date
2022-03-01
Status
COMPLETED
relationships
The graph out of here
drug
Oral Glucose Tolerance Test (OGTT)
drug
lead_sponsor
Emory University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Inflammation
indication
investigator
David R Goldsmith, MD
person